Sidoti Research Analysts Decrease Earnings Estimates for PRE

Prenetics Global Limited (NASDAQ:PRE) – Stock analysts at Sidoti decreased their Q1 2026 earnings per share estimates for shares of Prenetics Global in a note issued to investors on Monday, March 30th. Sidoti analyst A. Hantman now expects that the company will post earnings per share of ($0.77) for the quarter, down from their prior estimate of ($0.74). The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share. Sidoti also issued estimates for Prenetics Global’s Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($1.09) EPS, FY2026 earnings at ($3.55) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at $0.88 EPS, Q4 2027 earnings at $1.45 EPS and FY2027 earnings at $2.16 EPS.

Prenetics Global (NASDAQ:PRE) last issued its earnings results on Wednesday, February 18th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.22. The business had revenue of $36.60 million during the quarter, compared to analyst estimates of $36.15 million. Prenetics Global had a negative return on equity of 19.07% and a negative net margin of 61.33%.

A number of other equities analysts have also recently commented on PRE. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Prenetics Global from a “buy” rating to a “hold” rating in a research report on Monday, February 16th. Roth Mkm began coverage on Prenetics Global in a report on Wednesday, February 11th. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Lake Street Capital started coverage on Prenetics Global in a research note on Monday, March 16th. They issued a “buy” rating and a $29.00 target price for the company. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Prenetics Global presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.33.

Prenetics Global Stock Performance

Shares of PRE opened at $19.68 on Wednesday. Prenetics Global has a fifty-two week low of $3.09 and a fifty-two week high of $23.63. The firm has a market cap of $331.21 million, a price-to-earnings ratio of -4.90 and a beta of 0.27. The firm has a 50 day moving average price of $19.42 and a 200-day moving average price of $16.22.

Prenetics Global announced that its Board of Directors has authorized a share buyback program on Friday, March 6th that allows the company to repurchase $40.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 15.8% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Institutional Investors Weigh In On Prenetics Global

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN purchased a new stake in Prenetics Global during the 4th quarter valued at $47,000. JPMorgan Chase & Co. bought a new position in shares of Prenetics Global during the third quarter valued at about $65,000. Manatuck Hill Partners LLC bought a new position in shares of Prenetics Global during the fourth quarter valued at about $170,000. T3 Companies LLC purchased a new stake in shares of Prenetics Global during the fourth quarter worth about $170,000. Finally, Kingsview Wealth Management LLC purchased a new stake in shares of Prenetics Global during the fourth quarter worth about $172,000. 25.01% of the stock is currently owned by institutional investors.

Trending Headlines about Prenetics Global

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: High‑profile partnership and shareholder: Prenetics announced NBA champion and two‑time MVP Giannis Antetokounmpo as an IM8 Global partner and shareholder in a multi‑year deal — a marketing and brand win that could accelerate IM8 adoption, raise consumer awareness and drive sales of the company’s consumer diagnostics/supplement ecosystem. Prenetics Announces Giannis Partnership
• Positive Sentiment: Strategic products partnership: Prenetics’ collaboration with Superpower to pair clinical‑grade supplementation and blood diagnostics integrates testing with personalized supplements, strengthening Prenetics’ consumer health proposition and recurring‑revenue potential. Prenetics Partners with Superpower
• Positive Sentiment: Sidoti’s longer‑term upgrade: Analyst A. Hantman at Sidoti substantially raised FY2027 EPS to $2.16 (from $1.65) and boosted Q3/Q4 2027 and Q4 2027 estimates — signaling a path to profitability that can support a higher valuation if execution follows. (MarketBeat summary of the Sidoti note.) Sidoti Analyst Note
• Neutral Sentiment: Inclusion in retail lists: Prenetics was named among “7 fastest growing Asian stocks to buy” in a market roundup — positive PR but not a direct fundamental catalyst unless it drives sustained new investor flows. MSN: 7 Fastest Growing Asian Stocks
• Negative Sentiment: Near‑term estimate cuts by Sidoti: The same Sidoti note trimmed several near‑term 2026 quarter estimates (Q1–Q3 2026 and Q2 2026 were lowered modestly), indicating potential execution or margin risk in the short term that could pressure results before FY2027 improvements materialize.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.